Introduction {#s1}
============

Hair, in addition to the role of cuticle, is important cosmetically for human beings. Hair loss sometimes causes mental illness. Androgenic hair loss is one of the most common types of hair loss, which in men and women, is genetically predisposed, causing hair loss with a specific pattern.^[@R1]^ Androgenic hair loss, also called androgenetic alopecia, occurs because of the sensitivity of the field of follicles to androgens. Androgenic hair loss is the most common reason for hair loss in 70% of men and 40% of women. Head hair in humans, although having non-androgen-dependent growth, has a specific receptor for sex hormones, and therefore these hormones can affect hair loss. In men, the frontotemporal regions, or the front and back regions as well as the center of the head, feature such hormonal receptors, but in women, all hair of the head area has androgenic receptors. As a result, the pattern of hair loss in men begins from the front of the head (nodes) and then reaches the central area, while in women, there is usually hair thinning and spreading without hair strain. The typical pattern of male hair loss is because of genetic sensitivity to the effects of dihydrotestosterone (DHT) in certain areas of the scalp. Testosterone is converted to its active form, DHT, which induces hair loss and is linked to androgenic receptors in hair follicles, which results in compromised growth phase of the hair cycle. It is believed that DHT shortens the growth stage, or anagen, from a typical period of three to six years to several weeks or months. This causes the hair follicles to shrink gradually, reducing hair production and making hair smoother. DHT is produced by an enzyme called 5-alpha-reductase.^[@R2]^ Finasteride is a 5-alpha-reductase (II) inhibitor which is administered in the treatment of such hair loss and acne by pills that are either 1 or 5 mg in strength. The use of this drug systemically has side effects such as complications like gynecomastia, behavioral disorders and loss of libido. The drug has a molecular weight of 372.5 Da (Log p = 3). Its low solubility in water (11.7 mg/L) is another physicochemical feature of finasteride.^[@R3]^ Low molecular weight, short half-life (six hours) and ideal physicochemical properties means finasteride is suitable for use on the skin.

A very low dissolution of a drug may limit its efficacy. Therefore, increasing the solubility of the drug is effective for improving therapeutic efficacy and reducing the total dose of the drug, thereby minimizing its adverse side effects. Increasing solubility with surfactants is one of the most important techniques evaluated in this context. Research has shown that the most critical reason for increasing the dissolution of microemulsions (MEs) is the presence of "solubilizing sites" in the hydrophilic and lipophilic areas of superficial interphase films, which will enhance the dissolution of hydrophilic and lipophilic compounds. Additionally, the unique structure of phases in MEs contributes to the presence of more "dissolving regions", which increases the loading capacity of the drug in MEs compared with solutions containing the same proportion of the same components.^[@R4]^ A semi-solid form of MEs is one of the new formulas used as a topical delivery system.^[@R5],[@R6]^ MEs have many features unique as topical and transdermal drug delivery systems. First, the main advantage of these colloidal systems is that a large amount of the drug can be combined owing to the increased solubilization capacity, and therefore the thermodynamic activity in the skin increases with the gradient having a high concentration of the drug present in the ME for the skin. Second, the degree of drug penetration using ME carriers is improved based on the interaction of various components to increase the delivery of medication across the skin. Third, the main components, such as the water phase, oil phase and surfactant-co-surfactant mixtures, can be combined to increase the charge of the drug.^[@R7]^ Furthermore, it is believed that surfactants and oils interact within a ME via a bilayer lipid structure and act as permeation enhancers.^[@R8]^

Knowing the internal microstructures of ME systems, such as phase change behavior and drug release, are vital to solution capabilities. On the other hand, this feature also affects the production and fabrication of polymer nanoparticles from these systems.^[@R9]^

In this study, the design and creation of a suitable formulation of a ME was carried out. This ME designed with proper loading capacity, suitable release rate and acceptable stability, would enhance the proper passage of a drug through the skin. If MEs are able to raise the follicular absorption of a compound, therapeutic efficacy of the drug will definitely improve, as well.

The ultimate aim of this research was to formulate, characterize and evaluate *in vitro* skin permeability of a finasteride ME.

Materials and Methods {#s2}
=====================

Materials {#s2-1}
---------

Finasteride was purchased from Soha Helal (Tehran, Iran). Propylene glycol, Span 20, Tween 80, oleic acid, sodium dihydrogen phosphate and sodium hydrogen phosphate were obtained from Merck (Darmstadt, Germany). Transcutol P was donated by the Gattefosse (Lyon, France). The dialysis bags used in the present study was purchased from Tuba Azma Co. (Tehran, Iran). All chemicals and solvents were analytical grade. In addition, fresh double distilled water was used in the experiments.

Animals {#s2-2}
-------

Male Wistar rats weighing 150-170 g that were 10-12 weeks old were used in the present study, which was performed with the approval of the Animal Ethical Committee, Ahvaz Jundishapur University of Medical Sciences. Rat abdominal hair was removed without damage to the skin. Rat with high concentrations of thiopental were anesthetized and then sacrificed. Subcutaneous fat was cleansed at the inner surface of the skin with pure cold acetone. The thickness of the skin was measured with digital micrometers.

Finasteride assay {#s2-3}
-----------------

Determination of the amount of Finasteride was carried out by an ultraviolet (UV) spectroscopy method at λmax= 224 nm in buffer phosphate (pH = 7) and methanol 2:1.

Screening of oils, surfactants and co-surfactants for microemulsions {#s2-4}
--------------------------------------------------------------------

Transcutol P and oleic acid as oils, Tween 80, Span 20 as surfactants and Propylene glycol were selected as co-surfactant and Finasteride solubility with these agents was determined. As such, 5 mL of each of the ingredients was poured into a beaker and added to each finasteride solution at 25°C for 48 hours with stirring.^[@R10]^ The resulting mixture was centrifuged at a rate of 3000 rpm for 15 minutes and the solution and sediment were separated. The amount of the dissolved drug was determined at 224 nm wavelength by UV spectrophotometry.^[@R11]^

Pseudo-ternary phase diagram construction {#s2-5}
-----------------------------------------

The pseudo-ternary phase diagrams were created based on the information obtained from previous studies using Span 20 and Tween 80 surfactants, propylene glycol co-surfactant and the oil phase containing pleic acid and Transcutol P in ratios of 3:1 and 2:1, respectively. Based on the factorial design and pre-formulation trials with three variables at two levels for each variable, eight formulations were selected as presented in [Table 1](#T1){ref-type="table"}. Two levels of up-and-down were considered for each variable, and the variables in this study were the ratio of surfactant to co-surfactant (3:1 and 1:2), oil proportion (10 and 60%) and water content (5 and 10%). 1% of the drug was added to each formulation and examined.^[@R6],[@R12]^

###### Composition of selected ME formulation of finasteride

  -------- --------------- --------- ----------- ------------- -----------
           **Factorial**   **S/C**   **% Oil**   **% S + C**   **Water**
  ME-F-1   \+ + +          3:1       60          30            10
  ME-F-2   \- + +          3:1       60          35            5
  ME-F-3   \+ - +          3:1       10          80            10
  ME-F-4   \- - +          3:1       10          85            5
  ME-F-5   \+ - -          2:1       10          80            10
  ME-F-6   \- - -          2:1       10          85            5
  ME-F-7   \- + -          2:1       60          35            5
  ME-F-8   \+ + -          2:1       60          30            10
  -------- --------------- --------- ----------- ------------- -----------

Polarized light microscopy {#s2-6}
--------------------------

To corroborate the isotropic nature of MEs, the samples were examined using a polarized cross-sectional microscope (Olympus BX51 U-AN 360, Tokyo, Japan). A drop of ME sample was placed between the front and a glass slide to be observed under a polarized cross light. The isotropic material, such as a ME does not interfere with polarized light compared with anisotropic liquid crystals and a dark field of vision.^[@R13],[@R14]^

Preparation of finasteride microemulsions {#s2-7}
-----------------------------------------

MEs were employed for the construction of phase diagrams ([Figure 1](#F1){ref-type="fig"}) and full-factor design with three variables at two levels. Independent variables including the ratio of surfactant to co-surfactant (s/c), oil proportion and water proportion. Factorial design of eight formulations with high and low levels of oil (60% and 10%), water (10% and 5%), surfactant to corn ratios (2:1 and 3:1) and finasteride (1%) were prepared. Further, finasteride was added to a mixture of oil, then in a mixture of surfactants and co-surfactants; enough drops of distilled water were added to the mixture, which was then further mixed with the finasteride containing ME.^[@R15],[@R16]^
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Droplet size determination {#s2-8}
--------------------------

The droplet size of each of the MEs was evaluated by a particle size analyzer (Scatter Scope 1 Quidex, South Korea). The mean droplet size and dispersion index were measured.^[@R15],[@R17]^

pH and viscosity measures {#s2-9}
-------------------------

The samples were examined for viscosity. For this purpose, at 25 ± 0.5° C and with a Brookfield viscometer (Brookfield Engineering, Middleboro, Massachusetts, USA) , DV-II and Spindel 34 were measured in 10 ml volumes at shear rates of 75 rpm.18 The pH of the samples was measured with a Mettler (Mettler Toledo, Wan, Kowloon, Hong Kong) pH meter at 25° C without dilution.

Differential scanning calorimetry (DSC) {#s2-10}
---------------------------------------

A Mettler-Toledo DSC (Mettler Toledo, Wan, Kowloon, Hong Kong) was made use of to carry out the thermal analysis of MEs. For this purpose, a small amount of specimen was weighed in aluminum foam, and then the doors were completely closed so that they did not exchange any material with the outside environment. DSC was performed in cooling mode.15 In cooling mode, the samples were exposed to a temperature of +30° C to -50° C and a scan speed of 5°C/min. The rate of decrease in temperature was 5°C/min in this method.19 In this case, aluminum foam was used as a reference.

Drug release study {#s2-11}
------------------

Different formulations were utilized to investigate drug release from the Franz diffusion cells with a cross-sectional area of 3.4618 cm^2^. With this method, mixture buffer phosphate (pH = 7) and methanol (2:1) were selected as the receptor phase. An artificial cellulose membrane that was soaked in deionized water for 24 hours prior to testing was employed as a membrane model. To perform the test, the receiver was filled with 30 ml of receiver phase and placed on the styrene device at a temperature of 37 ± 0.5°C and with a magnet rate of 200 rpm. Next, 3 g of each formulation was weighed and spread on the membrane. The temperature setting of the receiver phase was set by the device.

At time zero, the magnet was turned on and contact with the membrane was initiated, being removed at specified intervals (0.5, 1, 2, 3, 4, 5, 6.7, 8 and 24 hours) from the receptacle; 2 mL of fresh solution was replaced by the receptor phase, and the amount of the drug was determined by a spectrophotometric method at 224 nm wavelength. The study was repeated three times for each of the examples.^[@R20]^

In order to establish the kinetic model of drug release, zero-order, first-order and Higuchi models were fit to the results, and the highest r^[@R2]^ was the criterion for selecting the model.

Physical stability of MEs {#s2-12}
-------------------------

With different formulations, several samples were prepared in 5 mL volumes and stored at 4, 25 and 37°C for six months. During this period, samples were examined each week for apparent characteristics (transparency, uniformity and droplet size variation). Any change, such as in the appearance of turbidity or separation of phases in formulations, was a sign of instability.^[@R21]-[@R23]^

Permeability experiments {#s2-13}
------------------------

Until the permeability testing, the skin was kept in a freezer. Before use, the skin samples were removed from the freezer and kept at room temperature to reach room temperature. Thereafter, they were cut into small pieces and placed on diffusion cells such that the stratum corneum was placed into donor phase and hydrated at 37°C for 16 hours between the phases of the receptor and donor, then the phases were evacuated. Inside the receptor with a volume of 22 mL, the receiver phase was poured out and 5 g of finasteride ME was poured into the compartment and a finasteride passage test was conducted on the entirety of the rat skin. However, the thickness of the samples and amount of hydration of the skin before and after initial contact with the phase of the receptor were measured.

To investigate the effect of MEs, after hydrating and placing the skin on Franz cells, 5 g of ME formulations were placed on the skin, and the receptor phase was filled with phosphate buffer (pH =7) and methanol (1:2) and placed on styrene. The receiver phase was stirred at 200 rpm with a magnet. At specific times (0.5, 1, 2..., 8, 24, 26, 28, 32, 36 and 48), sampling of the receiver phase was performed and 2 ml of the receiver phase was removed immediately at equal volumes from the fresh solvent to replace the sink conditions. The amount of drug was measured by UV spectroscopy at 224 nm. An ME without drug was used as a control.^[@R24]^

Data analysis and statistics {#s2-14}
----------------------------

The analysis of variance (ANOVA) method was employed to analyze the difference between the parameters of the permeation of finasteride in ME formulations. Minitab 17 software (Minitab, Inc, Pennsylvania, USA) was utilized to evaluate the effects of independent variables on dependent variables. Using Sigma Plot version14 software (Systat Software, Inc, San Jose, California, USA), for the proposed ratios, ternary phase diagrams were plotted and the best proportions that yielded the ME formulation were determined.

All studies were repeated three times, and values were expressed as mean of standard deviation. For statistical analysis, two-way *t* tests and ANOVAs were applied. To design the full-factorial test, Minitab 17 was used.

Enhancement ratios (ER) were calculated from [equation 1](#m1){ref-type="disp-formula"}.

$$ER = \frac{\text{Permeability~parameter~after~treatment}}{\text{Permeability~parameter~before~treatment}}$$

In this study, the penetration rate of finasteride in MEs was studied from whole rat skin and permeability parameters, such as passage rate in an equilibrium state (Jss), permeability coefficient (p), lag time (Tlag) and apparent diffusivity coefficient (Dapp), was calculated. In order to establish cross-flow parameters, cumulative volume of the drug passed through the surface unit versus time was plotted. The permeability coefficient (p) was calculated from [equation 2](#m2){ref-type="disp-formula"}^[@R25]^:

$$\text{J}_{ss} = \text{P} \times \text{C}$$

*C*: Drug concentration in the donor phase.

*Tlag*: clamping time of drug obtained from the skin along the line of equilibrium to the axis of time in the cumulative curve of the drug.

The value of *D* is calculated from [Equation 3](#m3){ref-type="disp-formula"}^[@R26]^:

$$D = \frac{\text{h}^{2}}{6\text{Tlag}}$$

As *h* does not represent the actual length of the pathway, the *D* calculated from this formula is also apparent to D. Seeing all calculations are based on the steady-state region, the cumulative flow rate of the drug is determined, so the establishment of sink conditions is indispensable for the citation of these parameters. In this work, the maximum concentration established in the receptor phase was less than 10% of the saturation solubility of the drug in the receptor phase, and therefore, a steady concentration gradient was established during the experiments, and with these conditions, a steady passage rate was computed.

Results {#s3}
=======

Solubility of finasteride {#s3-1}
-------------------------

The solubility of finasteride is found in [Table 2](#T2){ref-type="table"}.

###### Results of drug solubility in each of the components of microemulsion formulation (mean ± SD, n = 3)

  ---------------- ------------------------- ------------------------
  **Phase type**   **Excipient**             **Solubility (mg/mL)**
  Oil              Oleic acid                8.1 ± 0.1
  Oil              Transcutol P              15 ± 0.2
  Oil (mixture)    Oleic acid+Transcutol P   20.1 ± 0.4
  Surfactants      Span20                    3.2 ± 0.1
  Surfactant       Tween 80                  2.9 ± 0.2
  Co-surfactant    PG                        11 ± 0.3
  ---------------- ------------------------- ------------------------

Phase studies {#s3-2}
-------------

The pseudo-ternary phase diagrams of oleic acid-Transcutol P/Span 20-Tween 80/PG/water are presented in [Figure 1](#F1){ref-type="fig"}. ME structures were observed using cross-polarized light microscopy. [Figure 2](#F2){ref-type="fig"} depicts the black background for all formulations of MEs under polarized light microscopy.
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Characterization of finasteride MEs {#s3-3}
-----------------------------------

The viscosity, mean droplet size, polydispersity index (PI) and pH of finasterideMEs are located in [Table 3](#T3){ref-type="table"}.

###### Physicochemical parameters of MEs (mean ± SD, n = 3)

  -------- ----------- --------------------- ---------------------------- --------------------------
           **pH**      **Viscosity (cps)**   **Mean droplet size (nm)**   **Polydispersity index**
  ME-F-1   5.1 ± 0.1   97 ± 2.6              7.74 ± 1.6                   0.328 ± 0.016
  ME-F-2   5.2 ± 0.2   86.4 ± 3.4            7.12 ± 1.2                   0.333 ± 0.022
  ME-F-3   5.4 ± 0.1   209.6 ± 8.2           12.5 ± 1.4                   0.354 ± 0.008
  ME-F-4   5.4 ± 0.3   202.4 ± 3.8           16.95 ± 0.9                  0.334 ± 0.016
  ME-F-5   5.6 ± 0.3   193.6 ± 4.5           11.6 ± 0.1                   0.321 ± 0.0015
  ME-F-6   5.6 ± 0.1   183.3 ± 6.2           5.5 ± 2.4                    0.333 ± 0.002
  ME-F-7   5.7 ± 0.2   96 ± 3.4              13.14 ± 1.8                  0.338 ± 0.002
  ME-F-8   5.7 ± 0.1   104 ± 2.6             15.5 ± 5.4                   0.339 ± 0.003
  -------- ----------- --------------------- ---------------------------- --------------------------

The amount and kinetics underlying drug release from the MEs are presented in [Table 4](#T4){ref-type="table"}.

###### Percentage release and kinetic release of selected MEs (mean ± SD, n = 3)

  -------- ------------------------ ----------- --------------- ----------------
           **Kinetic of release**   **r** ^2^   **Q** ~2h(%)~   **Q** ~24h(%)~
  ME-F-1   Higuchi                  0.9897      10.6 ± 5.4      39.34 ± 1.11
  ME-F-2   Higuchi                  0.9857      7.918 ± 2.185   32.201 ± 4.039
  ME-F-3   first                    0.9966      7.457 ± 3.572   48.158 ± 1.250
  ME-F-4   first                    0.9946      5.977 ± 0.346   46.861 ± 2.704
  ME-F-5   first                    0.9985      4.897 ± 0.798   48.724 ± 2.430
  ME-F-6   first                    0.9992      5.303 ± 0.438   49.510 ± 3.292
  ME-F-7   Higuchi                  0.9933      6.402 ± 0.883   28.668 ± 4.903
  ME-F-8   first                    0.9906      6.230 ± 1.078   31.134 ± 0.086
  -------- ------------------------ ----------- --------------- ----------------

The results show that the percentage of 24-hour release of the drug from the MEs in formulation 6 is the highest and lowest in ME 7.

Thermal analysis was conducted on finasteride MEs by cooling. The results from determining the phase transition temperature and enthalpy of finasteride MEs in the cooling program are provided in [Table 5](#T5){ref-type="table"}.

###### Transition temperature and enthalpy of ME formulations of finasteride (mean ± SD, n = 3)

  -------- ------------------------------------ ----------------
           **T** ~m2~ **(°C))Melting Point)**   **ΔH (mj/mg)**
  ME-F-1   -27 ± 0.1                            44.22 ± 1.1
  ME-F-2   -27 ± 0.2                            50.43 ± 0.9
  ME-F-3   -30 ± 0.5                            1.01 ± 0.11
  ME-F-4   -31 ± 0.4                            0.64 ± 0.12
  ME-F-5   -31 ± 0.3                            0.96 ± 0.15
  ME-F-6   -32 ± 0.5                            0.62 ± 0.1
  ME-F-7   -48 ± 0.5                            26.88 ± 1.1
  ME-F-8   -33 ± 0.2                            29.73 ± 1.3
  -------- ------------------------------------ ----------------

It has been shown that all finasteride ME formulations have appropriate characteristics with regards to their homogeneity and stability over six months.

The permeability parameters of the finasteride ME formulations in comparison with saturation controls are given in [Table 6](#T6){ref-type="table"}.

###### permeability parameters of finasteride microemulsions compared with control ( mean ± SD, n = 3)

  --------- --------------------------- --------------------------------- ------------------- --------------------- --------------- --------------- --------------- ---------------
            **J** ~ss~ **(mg/cm2.h)**   **D** ~app~ **(cm** ^2^ **/h)**   **P(cm/h)**         **T** ~lag~ **(h)**   **ER\*** ~p~    **ER** ~flux~   **ER** ~D~      **ER** ~p~
  Control   0.0046 ± 0.0051             0.0116 ± 0.0006                   0.00045 ± 0.0005    4.67 ± 0.241          \-              \-              \-              \-
  ME-F-1    0.0322 ± 0.0126             0.0164 ± 0.0120                   0.0032 ± 0.0012     4.54 ± 0.345          21.97 ± 2.9     22.02 ± 1.2     1.38 ± 0.9      21.97 ± 2.9
  ME-F-2    0.0169 ± 0.0010             0.0100 ± 0.0075                   0.0017 ± 0.0001     7.53 ± 0.665          9.18 ± 0.8      9.18 ± 0.9      0.88 ± 0.6      9.18 ± 0.8
  ME-F-3    0.0107 ± 0.0009             0.0574 ± 0.0130                   0.0011 ± 8×10^-5^   1 ± 0.2               6.3 ± 1.13      6.31 ± 0.19     4.98 ± 1.3      6.3 ± 1.13
  ME-F-4    0.0194 ± 0.0009             0.0066 ± 0.0018                   0.0019 ± 8×10^-5^   8.48 ± 1.2            11.14 ± 2.458   11.1 ± 2.5      0.5617 ± 0.12   11.14 ± 2.458
  ME-F-5    0.0326 ± 0.0060             0.0202 ± 0.0026                   0.0032 ± 0.0006     2.69 ± 0.355          16.3 ± 2.6      16.45 ± 1.9     1.74 ± 0.14     16.3 ± 2.6
  ME-F-6    0.0456 ± 0.0024             0.8086 ± 0.12                     0.0045 ± 0.0003     1.65 ± 0.290          26.35 ± 2.5     26.32 ± 2.6     67.25 ± 3.02    26.35 ± 2.5
  ME-F-7    0.0241 ± 0.0066             0.0196 ± 0.005                    0.0024 ± 0.0006     2.85 ± 0.7            15.59 ± 1.6     15.58 ± 1.6     1.704 ± 0.51    15.59 ± 1.6
  ME-F-8    0.0281 ± 0.0205             0.0252 ± 0.0261                   0.0028 ± 0.0020     4.6 ± 0.790           22.13 ± 2.9     22.12 ± 2.94    2.117 ± 0.140   22.13 ± 2.9
  --------- --------------------------- --------------------------------- ------------------- --------------------- --------------- --------------- --------------- ---------------

Discussion {#s4}
==========

For introducing the appropriate formulation of finasteride ME, as well as introducing a mixture of oil, surfactants and appropriate co- surfactants, the degree of solubility of finasteride in each component was employed. Our study showed that mixtures of oleic acid and Transcutol P with a ratio of 10:1 as oil, mixtures of Span 20 and Tween 80 as surfactants and polyethylene glycol as co-surfactants were suitable. In addition, the phase diagram showed that with increasing the ratio of surfactants to co-surfactants, the width of the ME region increased.^[@R27]^

The droplet size of the MEs was in the range of 5.50 to 16.95 nm, which is within the range of MEs (1-100 nm).^[@R28]^ The relationship between the size of the droplet and independent variables has shown that the droplet size of MEs was not significant with any of the parameters.^[@R29]^ The particle size dispersion index (PDI) indicated the uniformity of droplet size in the MEs; The PDI values obtained in this study were less than 0.5 for all MEs. Therefore, the results indicated the uniformity of droplet size of the MEs. These results were consistent with the conclusions of previous articles.^[@R13]^

The viscosity of the MEs was within the range of 86.4 to 209.6 cps. Analysis of data variance showed that there is a significant relationship between the oil content (*P* \< 0.05) and theconstant of the equation (*P* \< 0.05), thus increasing the oil content leads to a rise in viscosity of the desired formulations. Additionally, given that equation *P* is less than 0.05, other formulation components also affected viscosity for the formulation of each ME.

The pH of the MEs was within the range of 5.1-5.7. Analysis of data variance suggested that the pH of the formulation with oil proportion (*P* = 0.170) and water content (*P* = 0.640) was not significant, but with the ratio of s/c (*P* \< 0.05) and constant of the equation (*P* \< 0.05), there was significance. Reduction of the s/c ratio increased pH. Moreover, owing to the significance of the constant of the equation, other formulation components were noted to influence pH. The studied MEs had suitable pH for the skin.

Drug release of finasteride MEs followed different kinetics. The analysis of the variance of the data for the MEs showed that the relationship between the percentage of drug release from the MEs with the oil content and ratio of s/c, the constant water content of the equation was not significant. The maximum amount of drug release in two hours happened in formulation ME-F-1, and the lowest amount of drug release at the second hour happened in formulation ME-F-5.

Diminishing oil content enhanced the release of the drug after 24 hours. ME-F-6 (containing 5% (w/w) water, 56.67% (w/w) surfactant, 10% (w/w) oil phase and 28.33% (w/w) co-surfactant) and ME-F-5 (containing 10% (w/w) water, 53.34% (w/w) surfactant, 10% (w/w) oil-phase and 26.66% (w/w) co-surfactant), which had a liberation proportion of 49.510 and 48.724%, respectively, the highest degree of release among the studied formulations. Based on the analysis of the variance of drug release data with the MEs, the percentage of drug release from MEs with oil content (*P* \< 0.05) and constant of the equation (*P* \< 0.05) were significant, while with other variables, there was no significance. Therefore, by increasing the proportion of oil in the MEs, the percentage of drug release increased after 24 hours. With high water levels, the amount of drug release was increased with a rising s/c ratio.

DSC studies were used in the cooling program to study the water behavior of the MEs. The water found in the MEs was both free water (bulk) and bonded water (between the surface). There are several reports of phase transfer temperatures for free water and water bonded in the DSC experiments.^[@R30]^

Podlogar et al reported limited free water at temperatures ranging from -8°C to 0°C and limited bonded water at temperatures ranging from -26° C to -17°C, demonstrating that if the water content is low in a ME, the freezing point of the bonded water was very low. The bottom (-45°C) showed that the water was tightly bonded to the surfactant. The distilled water employed had a sharp and large carrier in the range of -17°C, which was referred to as the freezing point of super frozen water. This water does not interact with other molecules in the ME system.^[@R31]^

The study of finasteride ME formulation thermograms showed that for all MEs, the free-flowing or bulk temperature range was at 0°C, but all thermograms had an exothermic peak in the range of -48°C to -27°C. This is related to water-bonded water, which is strongly bound to surfactant.30 The presence of the phase transition temperature in ME-F-1 in the range of -48° C indicated that the water was firmly attached to the surfactant, which is consistent with the results of Podlogar and colleagues.^[@R31]^

Bound melting transition temperature (Tm~2~) in finasteride MEs is related to the ratio of s/c (*P* \< 0.05) such that with increasing s/c ratios, Tm~2~ increases. The constant of the equation (*P* \< 0.05) with Tm~2~ shows that other materials in the formulation also affect this temperature.

Furthermore, with a high proportion of oil, increasing water content from 5% to 10% reduced the freezing point of water. On the other hand, a high percentage of oil rose with an increasing s/c ratio from 2 to 3 such that Tm~2~ increased.

Based on the analysis of the DSC cooling curves of finasteride MEs, it was found that there was no significant relationship between water content and entangled water (H2) enthalpy, but with the equation constant (*P* \< 0.05), oil proportion (*P* \< 0.05) and s/c ratio (*P* \< 0.05), there was significance. Considering the ability of oleic acid as the oil phase in the ME studied in terms of hydrogen bonding, it seems that the bonding effect on the thermal behavior of water in MEs is likely to be influenced.

Yet, the percentage of oil proportion, water proportion and s/c ratio, free radicals experience open flux in MEs so that the increase in free enthalpy rose with an increase in either of the three parameters. Concerning the enthalpy of bonded water, oil proportion and water proportion, there were significant effects, so by increasing the percentage of oil and reducing water content, enthalpy of bonded water increased.

In order to investigate the stability of MEs, a narrow PDI value was observed for the formulations of finasteride. This parameter could indicate the degree of stability of the carrier. MEs were uniformly prepared with a clear dispersion and without separation of phases after centrifugation. In previous studies on the sustainability of MEs, it has been shown that there is a complex relationship between zero interfacial tension and thermodynamic stability.^[@R32]^ Thus, finasteride MEs could protect a drug from degradation for a long time without antioxidants.

ME vehicles have been able to influence certain formulations in terms of distribution. A number of these vehicles have been seen to increase the distribution of the drug by 67-fold over the saturation control.

Our results indicated that the effect of ME structure had a greater effect on the amount of flux and P, mainly because of the increase in the oil phase and amount of surfactant formulation, increasing the amount of flux and P in ME with a high probability most likely because of the fluidization of the lipid matrix or loss of structure of the lipid tissue of the horn tissue by Oleic acid and the surfactant formulation system.

Previous studies have shown that Oleic acid acts as an absorption enhancer in MEs, causing intermittent lipid disturbances, and eventually a separate lipid phase as a pond within the peripheral space, facilitating the passage of the drug.^[@R33]^ On the other hand, oleic acid is likely to dissolve the ligation of the horny layer by diminishing the lipid-binding temperature.^[@R33],[@R34]^

Earlier work has clearly demonstrated the effect of adsorption on unsaturated fatty acids was greater than that of saturation, and among non-saturated fatty acids, dual bonding compounds exhibited a higher absorption effect. Cis compounds also have a more attractive influence on trans-space arrangement.^[@R35]^ Based on the presence of a non-saturated band with cis spatial arrangement because of the difference in makeup relative to the lipid chains present in the bilayer interlayer structure after entry, there is an induction of irregularities and reduction of the transition temperature of the gel phase to liquid crystal.^[@R36]^

Propylene glycol, with an effect similar to ethanol, accelerates the distribution of the drug in the stratum corneum and, to a lesser extent, disturbs the structure of cellular fats. The use of 10% propylene glycol, along with oleic acid, increases the effect of uptake.^[@R36]^ The absorption in different formulations varies.^[@R35]^ This agent has its own effects by locating keratin in the stratum corneum via occupation of hydrogen bonding sites.^[@R37]^

Surfactants have a direct impact on the properties of the skin barrier and indirect effects on the thermodynamic properties of drug substances from the vehicle to the skin. These thermodynamic properties lead to the release of the drug into the skin. Surfactant monomers penetrate into the skin by interfering with it, altering the properties of the skin barrier and facilitating the entry of the drug into the skin.^[@R38]^ Non-ionic surfactants change the power distribution of the drug in the skin.^[@R39]^ Surfactants enhance penetration of the drug by dissolving stratum corneum lipids.^[@R40]^ The strength of surfactant binding to proteins within the horn layer leads to an increase in their absorption properties.^[@R41]^ They also interfere with the keratin of the stratum corneum cells.^[@R42]^ Span 20 (sorbitan monolaurate) is a non-ionic surfactant that has strong absorption in the skin.^[@R35]^

The effect of MEs on the transfer of drug from rat skin compared to control (1% suspension) was calculated by calculating ER~Flux~, ER~P~ and ER~D~. The results showed that all ME formulations caused a significant increase in ERFlux, ER~P~ and ER~D.~

The relationship between the permeability parameters of the skin and independent variables showed that the parameters of T~Lag~ and J~ss~ with independent variables in the studied range were not significant.

In addition, the results showed that the P coefficient had a significant relationship with the constant of the equation, and with a modification to other components, the value of P can be changed.

The relationship between independent variables and apparent diffusivity coefficient (D~app~) shows that this parameter (D~app~) has a significant relationship with water content, so that with increasing water content, D~app~ increases.

The results have shown that all ME formulations have a greater effect on flux than the difiusivity coefficient.

According to the results presented herein, it was found that ME-F-6 had the highest rate of drug passage (J~ss~) was 26.32 times more than the control group, therefore being the most suitable formulation for transfusion from rat skin.

Conclusion {#s5}
==========

The current study showed that any change in the content and composition of MEs could change physicochemical characteristics and drug permeability parameters.

The selection of ME vehicle to a large extent may increase the stability of finasteride and help pass the drug through the skin. The kinetics of drug release from the vehicle were based on the Higuchi or first-order models, indicating a long release versus finasteride solution.
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